Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional)
Open
National Institutes of Health is offering grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications close on September 25, 2028.
From the official notice on Grants.gov, last changed August 27, 2026. Checked October 31, 2026.
- Award ceilingnot stated
- Award floornot stated
- Expected awardsnot stated
- Total fundingnot stated
- Cost sharingNot required
- Funding typeGrant
Key dates
| Posted | June 9, 2026 |
|---|---|
| Deadline | September 25, 2028 |
| Archived by Grants.gov | November 24, 2028 |
Add the deadline to your calendar
Who can apply
This opportunity is open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility. Foreign Organizations/Foreign Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
The purpose of this notice of funding opportunity (NOFO) is to support innovative basic, clinical, translational, and implementation science research relevant to HIV and substance use. This initiative encourages high risk high impact transformative studies that advance knowledge and strategies for HIV prevention, diagnosis, treatment and virus suppression in people who use substances and/or have a substance use disorder.
How to apply
- Read the full notice and attachments on Grants.gov. The notice is the official source for deadlines and requirements.
- Make sure your organization has an active SAM.gov registration and Unique Entity ID; registration can take several weeks.
- Register on Grants.gov and submit through Workspace before the deadline and time given in the notice. Our application guide walks through each step.
Questions go to National Institutes of Health, nidagmbemail@nida.nih.gov, 301-402-2541.
Questions people ask
Who can apply for Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional)?
National Institutes of Health accepts applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional)?
Closes September 25, 2028 (695 days left). Confirm the date and time in the official notice on Grants.gov.
Similar open grants
- Continuation of the Collaborative Islet Transplantation Registry (U01 Clinical Trial Not allowed)
- BRAIN Initiative Cell Atlas Network (BICAN): Coordinating Unit for Biostatistics, Informatics, and Engagement (CUBIE)
- Centers without Walls for mechanisms of neurodegeneration in Alzheimer’s disease-related dementias (ADRD)
- Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed)
- Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE, RP1 Clinical Trial Not Allowed)
- Exposomic Contributions to ADRD Pathology and Resilience